Adimab, Biogen Idec, GlaxoSmithKline deal

In separate deals, Adimab granted non-exclusive licenses to Biogen Idec and GlaxoSmithKline to internalize Adimab's yeast-based antibody discovery platform to

Read the full 203 word article

User Sign In